ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2440

First Results from the Prospective German Pregnancy Register

Rebecca Fischer-Betz1, Christina Bungartz2, Jutta Richter1, Angela Zink3, Matthias Schneider1, Anja Weiss2, Joachim Listing4 and Anja Strangfeld5, 1Department of Rheumatology & Hiller Research Unit, Heinrich-Heine-University, Duesseldorf, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Epidemiology Unit, German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, 4German Rheumatism Research Center, Berlin, Germany, 5Epidemiology, German Rheumatism Research Center, Berlin, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biologic drugs, pregnancy, rheumatic disease and women's health, Safety issues

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Reproductive Issues in Rheumatic Disorders - Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: There is limited evidence on the safety of treatment during pregnancy and lactation. With the increasing number of new therapeutic options for inflammatory rheumatic diseases, there is a growing need for real-life data. Prospective randomized studies are not conducted in women who are pregnant or wish to conceive. The purpose of our register is to determine the safety of various drug treatments during pregnancy and the influence of the underlying rheumatic disease on pregnancy outcome and child development.

Methods: The Rhekiss register is designed as a web-based nationwide cohort study. Pregnant patients with confirmed diagnosis of inflammatory rheumatic disease are enrolled until the 20th week of pregnancy regardless of treatment. Rheumatologists and patients report each trimester during pregnancy and semi-annually after birth until the child’s 2nd birthday. Information on all given drug treatments, the course of the maternal disease, maternal or fetal complications during pregnancy, pregnancy outcomes and child development are collected. At first visit sociodemographic parameters, prior pregnancies, and comorbidities are reported. Only pseudonymized data are used, data security issues conform with regulatory authorities have been implemented.

Results: The register started on 15th of September 2015. Until end of May 2016, 84 rheumatologists recruited 200 pregnant women. We report first data of 182 patients. Of these, 28% had rheumatoid arthritis (RA), 23% systemic lupus erythematosus, 19% other connective tissue diseases, 18% spondyloarthritis or psoriatic arthritis, 6% juvenile idiopathic arthritis (JIA), 4% autoinflammatory diseases and 2% systemic vasculitis. Mean age of all patients was 32.5 (± 4.6) years, mean disease duration 8.3 (± 7.5) years. Mean disease activity over all diagnoses assessed by the rheumatologist on a numeric rating scale from 0-10, was 2.3 (± 2.1). On a disease severity scale ranging from 1 to 5 (highest grade), two thirds of all patients were reported grade 2 or 3. With respect to the different underlying diseases up to 60 % received treatment with biological DMARDs within 12 months before first visit, mainly patients with RA or JIA. One quarter of these patients continued biological DMARDs at least until conception.

Conclusion: The German pregnancy register Rhekiss was initiated to fill the knowledge gap on the course and outcomes of pregnancies in patients with rheumatic diseases as well as on the current use and safety of treatments during pregnancy and lactation. The fast uptake of patients shows that there is a substantial need for and a high interest in real-life data to guide treatment decisions


Disclosure: R. Fischer-Betz, None; C. Bungartz, None; J. Richter, None; A. Zink, None; M. Schneider, None; A. Weiss, None; J. Listing, None; A. Strangfeld, None.

To cite this abstract in AMA style:

Fischer-Betz R, Bungartz C, Richter J, Zink A, Schneider M, Weiss A, Listing J, Strangfeld A. First Results from the Prospective German Pregnancy Register [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/first-results-from-the-prospective-german-pregnancy-register/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/first-results-from-the-prospective-german-pregnancy-register/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology